Aurum Biosciences United Kingdom

Mr Gerry McGettigan
Mr Jim McGuire

Chronos Therapeutics United Kingdom

Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system.

Dr Huw Jones
Dr Helen Kuhlman
VP Corporate Development 

Cypralis Ltd United Kingdom

Cypralis was spun out from Selcia Ltd (Ongar, Essex) in 2013 to exploit its extensive expertise and know-how in targeting peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets involved in many acute and chronic diseases. Cypralis is dedicated to the discovery and development of innovative therapeutics for the inhibition of PPIases and expects to build upon its existing intellectual property estate through its own R&D activities and also through risk-sharing collaborations with pharmaceutical companies.

Mr Simon Kerr
Dr Michael Peel

Inivata Ltd United Kingdom

Dr John Beeler
VP Bus Dev 

Jupiter Diagnostics United Kingdom

When our CEO, Chris Ball worked as a doctor, he discovered that an urgent blood test usually meant waiting around for hours to get a result - and this was in a busy hospital. While working at Johnson & Johnson, he saw how rapid blood glucose testing could empower patients and accelerate clinical decision-making.  

However no rapid and accurate blood testing was widely available, so he began to look for technology which could deliver high-quality affordable blood testing anywhere. The result is Jupiter Diagnostics.
Dr Christopher Ball

Mironid United Kingdom

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Dr Neil Wilkie

Nanomerics Ltd United Kingdom

Professor Ijeoma Uchegbu
Chief Scientific Officer 

NIHR Clinical Research Network United Kingdom

Mr Matthew Cooper
Business Development & Marketing Director 

Oppilotech Ltd United Kingdom

We are building the most detailed, dynamic, in-silico model of bacterial cell envelope biogenesis, ever assembled. The model is being utilised as a platform to discover and develop an internal pipeline of new antibacterial drugs.

Dr Ajay Mistry
Dr John George
Dr Cora Griffin

OxStem United Kingdom

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology. 

The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.

Dr Michael Stein
Chairman and CEO 
Dr Carolyn Porter
Chief Business Officer 
Mr Raymond Spencer